<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580447</url>
  </required_header>
  <id_info>
    <org_study_id>183018</org_study_id>
    <nct_id>NCT03580447</nct_id>
  </id_info>
  <brief_title>The Effect of Citrus Extract on Oxidative Stress</brief_title>
  <official_title>The Effect of Citrus Extract Administration on Markers of Oxidative Stress in Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, cross-over, double-blind, placebo-controlled trial aims to determine the
      effects of daily administration of citrus extract over a period of 4 weeks on markers of
      oxidative stress in elderly.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2018</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>Change from baseline to four weeks supplementation, of each intervention period</time_frame>
    <description>Oxidative stress, as measured by blood biomarkers</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>Citrus extract</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During this period participants receive daily citrus extract supplements for four weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During this period participants receive daily maltodextrin supplements for four week</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Citrus extract</intervention_name>
    <description>Citrus extract</description>
    <arm_group_label>Citrus extract</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy individuals

          -  Age 70-85 years

          -  BMI &lt; 30 kg/m2

        Exclusion Criteria:

          -  History or actual status of severe cardiovascular, respiratory, urogenital,
             gastrointestinal/ hepatic, hematological/immunologic, HEENT (head, ears, eyes, nose,
             throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional,
             endocrine, neurological diseases, major surgery and/or laboratory assessments which
             might limit participation in or completion of the study protocol.

          -  Disease with a life expectancy shorter than 5 years

          -  Institutionalized (e.g. hospital or nursing home).

          -  Subjects with abnormalities in haematology which may interfere with the endpoints of
             the study (to be decided by the principle investigator)

          -  Use of drugs or hormones within 3 months prior to the start of the study which may
             interfere with the endpoints of the study (to be decided by the principle
             investigator)

          -  Self-admitted Inflammation, (viral) infection (e.g. HIV or hepatitis B)

          -  Subjects with an autoimmune disease (e.g. Rheumatoid arthritis)

          -  Subjects with intestinal disorders which may interfere with the endpoints of the study
             (to be decided by the principle investigator)

          -  Use of immunosuppressive drugs within 3 months prior to the start of the study

          -  Use of medication (e.g. NSAIDs), antibiotics or corticosteroids which may interfere
             with the endpoints of the study (to be decided by the principle investigator)

          -  Changes in medication that may significantly affect the study outcome (according to
             the investigator's judgment) within 1 month prior to the start of the study.

          -  Use of investigational drugs or participation in any scientific intervention study
             which may interfere with this study (to be decided by the principle investigator) in
             the 180 days before the study

          -  Use of (dietary) supplements containing antioxidants, vitamins and minerals

          -  Smoking

          -  Weight gain or loss (&gt; 3 kg in the previous 3 months)

          -  Excessive intake of foods with a high polyphenol concentration

          -  Use of pre-, pro or synbiotics within 1 month prior to the start of the study

          -  Blood donation within 1 month prior to the start of the study

          -  Excessive alcohol consumption (&gt;20 alcoholic consumptions per week)

          -  History of any side effects towards the intake of flavonoids or citrus fruits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ad Masclee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maastricht University Medical Center</investigator_affiliation>
    <investigator_full_name>Yala Stevens</investigator_full_name>
    <investigator_title>MSc.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

